Hypnotics and Sedatives
13
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
23%
3 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (13)
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy
Dexmedetomidine for Analgosedation to Newborn Infants During Neonatal Intensive Care
Comparison of Ciprofol-based and Propofol-based Total Intravenous Anesthesia on Postoperative Quality of Recovery
Clonidine for Analgesia to Preterm Infants During Neonatal Intensive Care
Bispectral Index and Patient State Index During General Anesthesia With Remimazolam
Comparison Between Natural Sleep Endoscopy and Drug-induced Sleep Endoscopy in Patients With Obstructive Sleep Apnea
Evaluation of Sedation in COVID-19 ARDS
Monitoring and Risk Prediction of Iatrogenic Sedative Hypnotics Addiction in a Shanghai Psychiatric Hospital
Acceptable Hemodynamic Changes in Dexmedetomidine for Single Intravenous Bolus Injection
Generalized Versus Personalized Music Therapy in the ICU to Reduce Sedation
Longitudinal Analysis of Drug Burden Index